André Trouet

Medicine · Health Sciences

34h-index5.3kcitations134works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Treatment and Pharmacology(17), Iron Metabolism and Disorders(15), Chemotherapy-induced cardiotoxicity and mitigation(12), Drug Transport and Resistance Mechanisms(10), Cancer therapeutics and mechanisms(9)

Publications134 total

First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours
European Journal of Cancer·2017· 19 cited
Abstract 5353: Efficacy of an innovative, enzyme-activated doxorubicin prodrug in patient-derived dedifferentiated liposarcoma and synovial sarcoma xenograft models
Cancer Research·2015· 1 cited
Preclinical Toxicity, Toxicokinetics, and Antitumoral Efficacy Studies of DTS-201, a Tumor-Selective Peptidic Prodrug of Doxorubicin
Clinical Cancer Research·2008· 30 citedOpen Access
Results of a first-in-man phase I study assessing the safety and pharmacokinetics of a one hour intravenous infusion of DTS-201 every 3 weeks in patients with advanced or metastatic solid tumors
Molecular Cancer Therapeutics·2007
Improved Therapeutic Efficacy of Doxorubicin through Conjugation with a Novel Peptide Drug Delivery Technology (Vectocell)
Journal of Medicinal Chemistry·2006· 53 cited
Transferrin Uptake by Cultured Rat Embryo Fibroblasts
European Journal of Biochemistry·2005· 134 citedOpen Access
CPI-0004Na, a new doxorubicin prodrug, reduces growth of 3LL-H61 carcinoma lung metastases in C57BI/6 mice.
PubMed·2004· 2 cited
Proliferation of smooth muscle cells and adhesion of monocytes in a coculture model of the arterial wall.
DIAL (Catholic University of Leuven)·2004
Coelenterazine: a two-stage antioxidant in lipid micelles
Free Radical Biology and Medicine·2003· 10 cited
Interaction of ochratoxin A with human intestinal Caco-2 cells: possible implication of a multidrug resistance-associated protein (MRP2)
Toxicology Letters·2003· 93 cited
CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
PubMed·2002· 34 cited
Improved activity of CPI-0004Na, a new doxorubicin prodrug, in an experimental metastasis model
DIAL (Catholic University of Leuven)·2002
<i>N</i>-Succinyl-(β-alanyl-<scp>l</scp>-leucyl-<scp>l</scp>-alanyl-<scp>l</scp>-leucyl)doxorubicin:  An Extracellularly Tumor-Activated Prodrug Devoid of Intravenous Acute Toxicity
Journal of Medicinal Chemistry·2001· 76 cited
S-nitrosothiols do not induce oxidative stress, contrary to other nitric oxide donors, in cultures of vascular endothelial or smooth muscle cells
European Journal of Pharmacology·2001· 23 cited
Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies.
PubMed·2001· 68 cited
Smooth Muscle Cells Influence Monocyte Response to LDL as well as Their Adhesion and Transmigration in a Coculture Model of the Arterial Wall
Journal of Vascular Research·2001· 20 cited
Announcement
Journal of Vascular Research·2001Open Access
Membership of the ESM
Journal of Vascular Research·2001
Conference Calendar
Journal of Vascular Research·2001Open Access
Protection against nitrofurantoin-induced oxidative stress by coelenterazine analogues and their oxidation products in rat hepatocytes
Free Radical Research·2001· 19 cited
page 1 of 7Next →

Frequent Co-authors

Yves‐Jacques Schneider(16), Jean‐Noël Octave(10), Robert R. Crichton(9), Paul M. Tulkens(6), R. Baurain(6), Anne-Marie Fernandez(4), Thomas J. Lobl(3), Cecilia Oliyai(3), Dan Shochat(3), Vincent Dubois(3), Fabienne Kinard(3), Claude Remacle(3), Christian de Duve(2), Valérie Berger(2), Yvan Larondelle(2), Ghanem Atassi(2), Kim Van derpoorten(2), Luc Dasnois(2), Karim Lebtahi(2), Vincent Dubois(2)